PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.50%
Net income growth similar to AXSM's 11.39%. Walter Schloss would find parallel expansions or market conditions in both firms’ profitability.
-31.48%
Negative yoy D&A while AXSM is 2.71%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-66.70%
Negative yoy deferred tax while AXSM stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
10.78%
SBC growth while AXSM is negative at -27.12%. John Neff would see competitor possibly controlling share issuance more tightly.
-179.22%
Both reduce yoy usage, with AXSM at -209.60%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-302.85%
Both negative yoy AP, with AXSM at -206.45%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-91.10%
Negative yoy usage while AXSM is 186.56%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
10.78%
Well above AXSM's 1.70%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-32.84%
Both yoy CFO lines are negative, with AXSM at -6.93%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-1.01%
Both yoy lines negative, with AXSM at -17.11%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1225.23%
We reduce yoy other investing while AXSM is 100.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-1611.06%
Both yoy lines negative, with AXSM at -17.11%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Both yoy lines negative, with AXSM at -100.06%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.